RECURRENT CANCER
Clinical trials for RECURRENT CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CANCER trials appear
Sign up with your email to follow new studies for RECURRENT CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Some participants will also receive an …
Matched conditions: RECURRENT CANCER
Phase: PHASE1, PHASE2 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Custom-Made vaccine trains immune system to attack tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor mutations. It aims to help the immune system recognize and attack cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal is to see if th…
Matched conditions: RECURRENT CANCER
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New radiation rod technique offers hope for Hard-to-Treat gynecologic cancers
Disease control Recruiting nowThis study is for people with cervical cancer or pelvic cancer that has come back, where the usual internal radiation (brachytherapy) cannot be used because of unusual anatomy or large tumors. Researchers are testing a special radiation technique called spatially fractionated rad…
Matched conditions: RECURRENT CANCER
Phase: NA • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New cocktail aims to tame Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combination can stop the cancer from growing for at least 6…
Matched conditions: RECURRENT CANCER
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC